<?xml version="1.0" encoding="UTF-8" ?> 
<rss version="2.0"> 
<channel> 
  <title>연구개발 보도자료 - 뉴스와이어</title>  
  <link>https://www.newswire.co.kr/?md=A02&amp;cat=112</link>  
  <description>연구개발 보도자료 - 뉴스와이어 RSS 서비스</description>  
  <lastBuildDate>Mon, 26 Oct 2026 19:58:23 +0900</lastBuildDate>  
  <copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright>  
  <webMaster>gichan2@newswire.co.kr</webMaster>  
  <language>ko</language>  
 <image> 
  <title>Newswire</title>  
  <url>https://static.newswire.co.kr/images/logo/logo_rss.png</url>  
  <link>https://www.newswire.co.kr</link>  
  <description>Newswire - 보도자료 통신사 뉴스와이어</description>  
 </image> 
  <item> 
  <title> 
  <![CDATA[입셀, 골관절염 치료제 ‘뮤콘’ 30명 대상 임상연구 투여 완료… 주지현 대표 국제학회서 성과 발표]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045520&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[<table border=0 align=left cellspacing=0 cellpadding=0 cellpadding=3 style='font-size:100%;font-family:arial,sans-serif'><tr><td width=80 align=center style='padding-left:6px;' valign=top><a href='https://www.newswire.co.kr/newsRead.php?no=&amp;sourceType=rss' target=nw><img src="https://file.newswire.co.kr/data/datafile2/thumb/2026/10/2038766241_20261026105645_8361798715.jpeg" width="80" border="0" /></a></td></tr></table>서울--(뉴스와이어)--유도만능줄기세포(iPSC) 기반 재생의료 기업 입셀이 가톨릭대학교 임예리 교수팀과 공동 개발 중인 골관절염 세포치료제 후보물질 ‘뮤콘(MIUChon)’의 30명 대상 임상연구 투여를 완료했다. 주지현 입셀 대표는 일본 교토에서 열린 iPSC 발견 20...]]> 
  </description> 
  <pubDate>Mon, 26 Oct 2026 12:00:00 +0900</pubDate> 
  </item> 
  <item> 
  <title> 
  <![CDATA[패치 나오기 전 공격 완성… OrcaRouter, AI로 PHP 취약점서 작동하는 공격 증명 스스로 작성]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045449&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[<table border=0 align=left cellspacing=0 cellpadding=0 cellpadding=3 style='font-size:100%;font-family:arial,sans-serif'><tr><td width=80 align=center style='padding-left:6px;' valign=top><a href='https://www.newswire.co.kr/newsRead.php?no=&amp;sourceType=rss' target=nw><img src="https://file.newswire.co.kr/data/datafile2/thumb/2026/10/3036617592_20261023222824_8389888769.png" width="80" border="0" /></a></td></tr></table>싱가포르--(뉴스와이어)--컨티뉴엄 AI(CONTINUUM AI)가 개발한 OrcaRouter 는 2026년 10월 22일 공식 채널을 통해 사이버 모델 OrcaCyber Zero 1.5가 PHP의 치명적 원격 코드 실행 취약점 두 건을 조사해 작동하는 공격 증명(Proof of Concept)을 스스로 작성했다고 ...]]> 
  </description> 
  <pubDate>Mon, 26 Oct 2026 09:39:20 +0900</pubDate> 
  </item> 
  <item> 
  <title> 
  <![CDATA[비원, ESMO 2026에서 치료가 어려운 간암 및 폐암에 대한 주목할 만한 데이터 발표]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045488&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[산 카를로스, 캘리포니아--(Business Wire/뉴스와이어)--글로벌 종양학 회사인 비원 메디신스 (BeOne Medicines Ltd.)(나스닥: ONC, 홍콩증권거래소: 06160; 상하이증권거래소: 688235)는 유럽 종양학회(European Society for Medical Oncology, ESMO) 2026 학술대회...]]> 
  </description> 
  <pubDate>Sun, 25 Oct 2026 15:25:00 +0900</pubDate> 
  </item> 
  <item> 
  <title> 
  <![CDATA[BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045489&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[SAN CARLOS, Calif.--(Business Wire/Korea Newswire)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid ...]]> 
  </description> 
  <pubDate>Sun, 25 Oct 2026 15:25:00 +0900</pubDate> 
  </item> 
  <item> 
  <title> 
  <![CDATA[문디파마, IDWeek 2026에서 최신 연구 구두 발표 형식으로 ReSPECT 3상 임상시험 추가 결과 발표]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045480&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[캠브리지, 영국--(Business Wire/뉴스와이어)--문디파마(Mundipharma)는 오늘 동종 조혈모세포 이식(allo-HSCT)을 받는 성인 환자의 침습성 진균 질환(IFD) 예방을 위한 레자요(REZZAYO®)(레자펀진 아세테이트)의 글로벌 3상 ReSPECT 임상시험의 추가 결과를 발표했...]]> 
  </description> 
  <pubDate>Sun, 25 Oct 2026 14:25:00 +0900</pubDate> 
  </item> 
  <item> 
  <title> 
  <![CDATA[Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 2026]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045481&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[CAMBRIDGE, England--(Business Wire/Korea Newswire)--Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adul...]]> 
  </description> 
  <pubDate>Sun, 25 Oct 2026 14:25:00 +0900</pubDate> 
  </item> 
  <item> 
  <title> 
  <![CDATA[비원 메디신스, 1차 치료 HER2+ 위식도암에서 테빔브라-지헤라 병용에서의 지속적인 생존 혜택 보고]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045474&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[산 카를로스, 캘리포니아--(Business Wire/뉴스와이어)--글로벌 종양학 기업인 비원 메디신스(BeOne Medicines Ltd.)(Nasdaq: ONC; HKEX: 06160; SSE: 688235)가 HER2 양성 국소 진행성 또는 전이성 위식도 선암(GEA) 환자의 1차 치료로서 테빔브라(TEVIMBRA®)(티슬...]]> 
  </description> 
  <pubDate>Sun, 25 Oct 2026 13:25:00 +0900</pubDate> 
  </item> 
  <item> 
  <title> 
  <![CDATA[BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045475&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[SAN CARLOS, Calif.--(Business Wire/Korea Newswire)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analy...]]> 
  </description> 
  <pubDate>Sun, 25 Oct 2026 13:25:00 +0900</pubDate> 
  </item> 
  <item> 
  <title> 
  <![CDATA[브레누스 파마의 새로운 체내 면역요법 STC-1010, 1차 치료 MSS 전이성 대장암에서 안전성 입증 및 T세포 활성화, 완전반응 2건 확인]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045472&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[마드리드--(Business Wire/뉴스와이어)--임상 단계 바이오테크 기업 브레누스 파마(Brenus Pharma)는 BreAK CRC-001의 1a상 용량 증량 시험에서 얻은 최초 데이터를 발표했다. 절제 불가능한 환자 9명이 치료를 받았으며, 89%는 간 전이가 있었고 89%는 KRAS 변이 종...]]> 
  </description> 
  <pubDate>Sun, 25 Oct 2026 13:05:00 +0900</pubDate> 
  </item> 
  <item> 
  <title> 
  <![CDATA[Brenus Pharma’s Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045473&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[MADRID--(Business Wire/Korea Newswire)--Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant...]]> 
  </description> 
  <pubDate>Sun, 25 Oct 2026 13:05:00 +0900</pubDate> 
  </item> 
  <item> 
  <title> 
  <![CDATA[Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045468&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[OSAKA, Japan & CAMBRIDGE, Mass--(Business Wire/Korea Newswire)--Takeda (TSE:4502/NYSE:TAK ) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Cla...]]> 
  </description> 
  <pubDate>Sun, 25 Oct 2026 12:40:00 +0900</pubDate> 
  </item> 
  <item> 
  <title> 
  <![CDATA[레노버, 입증되고 검증된 사용 사용 사례로 AI 라이브러리 확장해 비즈니스 성과 가속화 및 토큰당 가치 향상 도모]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045421&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[모리스빌, 노스캐롤라이나--(Business Wire/뉴스와이어)--레노버가 레노버 AI 라이브러리 를 새로운 검증된 AI 사용 사례로 확장하여, 조직이 맞춤형 구현 대비 최대 24배 더 빠르게[1] AI 실험에서 측정 가능한 비즈니스 성과로 전환할 수 있도록 지원하는 엔터프라...]]> 
  </description> 
  <pubDate>Fri, 23 Oct 2026 15:15:00 +0900</pubDate> 
  </item> 
  <item> 
  <title> 
  <![CDATA[Lenovo Expands AI Library with Proven, Validated Use Cases to Accelerate Business Outcomes and Drive Greater Value Per Token]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045425&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[MORRISVILLE, N.C.--(Business Wire/Korea Newswire)--Lenovo today expanded the Lenovo AI Library  with new, validated AI use cases, extending its portfolio of enterprise-ready solutions that can help organizations move from AI experimentation to mea...]]> 
  </description> 
  <pubDate>Fri, 23 Oct 2026 15:15:00 +0900</pubDate> 
  </item> 
  <item> 
  <title> 
  <![CDATA[A New Approach to Urban Traffic Congestion: BT Proposes Nonstop, High-Speed, High-Capacity Transit]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045364&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[<table border=0 align=left cellspacing=0 cellpadding=0 cellpadding=3 style='font-size:100%;font-family:arial,sans-serif'><tr><td width=80 align=center style='padding-left:6px;' valign=top><a href='https://www.newswire.co.kr/newsRead.php?no=&amp;sourceType=rss' target=nw><img src="https://file.newswire.co.kr/data/datafile2/thumb/2026/10/990877673_20261023091010_7016784294.jpg" width="80" border="0" /></a></td></tr></table>GWANGJU--(Korea Newswire)--BT Corp., a transportation research company based in Gwangju, South Korea, has introduced Branch Transit (BT), a new urban transportation concept designed to enable nonstop travel and high-capacity passenger transport by...]]> 
  </description> 
  <pubDate>Fri, 23 Oct 2026 09:54:44 +0900</pubDate> 
  </item> 
  <item> 
  <title> 
  <![CDATA[EggNest®, 미국심장협회저널 논문 발표 및 텍사스주 규제 예외 승인으로 중재시술실의 납 방호복 미착용 방식 전환 가능성 입증]]> 
  </title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045332&amp;sourceType=rss</link> 
  <category></category> 
  <description> 
  <![CDATA[<table border=0 align=left cellspacing=0 cellpadding=0 cellpadding=3 style='font-size:100%;font-family:arial,sans-serif'><tr><td width=80 align=center style='padding-left:6px;' valign=top><a href='https://www.newswire.co.kr/newsRead.php?no=&amp;sourceType=rss' target=nw><img src="https://file.newswire.co.kr/data/datafile2/thumb/2026/10/3717472907_20261022154235_1626574986.png" width="80" border="0" /></a></td></tr></table>미니애폴리스, 미네소타--(뉴스와이어)--에그 메디컬(Egg Medical)은 자사의 방사선 방호 장치인 에그네스트 강화형 방사선 방호 장치(EggNest Enhanced Radiation Protection Devices, ERPDs) 의 성능을 평가한 전향적 연구(prospective study)  결과가 미국심장협...]]> 
  </description> 
  <pubDate>Thu, 22 Oct 2026 16:47:19 +0900</pubDate> 
  </item> 
</channel> 
</rss> 
